Poor
Not Aligned
Patient Risk:
High
Summary
Several key claims are not supported by the provided prescribing information and multiple claims are contradicted (notably topical acyclovir ointment and cold sores/HSV indication). Additional efficacy/timing and mechanism statements are absent from the supplied label excerpts, leading to poor overall alignment.
Category Scores
Accurate Statements
Older adults may require a lower dosage of acyclovir due to decreased kidney function.
CLINICAL PHARMACOLOGY (Geriatrics): dosage reduction may be required in geriatric patients with underlying renal impairment; age-related renal function changes.
Common side effects of acyclovir include headache and nausea.
ADVERSE REACTIONS: headache listed in post-approval/clinical practice; nausea listed as most frequent (e.g., herpes simplex long-term administration and control patients).
Unsupported Statements
Acyclovir is a synthetic nucleoside analogue that works by inhibiting the replication of the herpes virus.
No such mechanism description is present in the provided label excerpts (only pharmacokinetics and study outcomes provided).
When taken orally, acyclovir can start working within 30 minutes to 1 hour after administration.
No time-to-effect statement in the provided label excerpts.
Dosage and frequency of acyclovir administration can impact how quickly the medication works.
The provided label excerpts do not state that dosage/frequency affects onset of effect in the way claimed.
Individual patient factors such as age, weight, and overall health can influence how quickly acyclovir works.
The label excerpts discuss renal function/geriatrics and dose adjustment but do not support the specific claim about 'how quickly it works' or include weight/overall health as stated.
Acyclovir should be taken as directed by a healthcare provider and not as needed.
The provided excerpts do not include the 'not as needed' instruction; they instead describe regimens and timing based on earliest sign/symptom in some indications.
Oral acyclovir is absorbed into the bloodstream and travels to the site of infection to inhibit viral replication.
Oral pharmacokinetics are described, but the supplied excerpts do not state 'travels to the site of infection' or 'inhibits viral replication' as a mechanism.
Topical acyclovir provides localized relief from itching, burning, and blistering.
No topical ointment indication or localized symptom-relief claim is present in the provided label excerpts.
Topical acyclovir can start working within 30 minutes to 1 hour after application.
No topical route/timing claim exists in the provided label excerpts.
Oral acyclovir is typically taken 2-5 times a day, depending on the severity of the infection and the patient's age.
The label excerpts provide specific regimens by indication (e.g., 5 times daily, twice daily), but do not support this broad 'typically 2-5 times daily' rule or the specific link to severity 'and patient's age' as stated.
Topical acyclovir ointment is commonly used to treat cold sores.
The provided label excerpts list indications for herpes zoster, genital herpes, and chickenpox, and do not include topical ointment use or cold sores/HSV-1 oral herpes.
Common side effects of acyclovir include fatigue.
The provided excerpts list 'malaise' (not fatigue) as most frequent for herpes zoster; 'fatigue' is not supported in the provided data.
Contradictions
High
AI Statement
Acyclovir is available in oral tablets, capsules, and topical ointment.
Label Reference
DOSAGE AND ADMINISTRATION (provided excerpts): discusses oral formulations (capsules/tablets/oral suspension) and IV administration; no topical ointment is described in the supplied label excerpts.
High
AI Statement
Topical acyclovir ointment can start working within 30 minutes to 1 hour after application.
Label Reference
No topical ointment route and no onset-time statement are present in the provided label excerpts.
High
AI Statement
Acyclovir is a antiviral medication used to treat herpes simplex virus (HSV) infections, including cold sores and genital herpes.
Label Reference
INDICATIONS AND USAGE (provided excerpts): includes genital herpes and does not include cold sores/HSV-1 oral herpes. (HSV term is broader than the provided indications.)
Important Omissions
For treatment of chickenpox and herpes zoster/genital herpes, the label excerpts specify detailed dosing schedules and initiation timing (e.g., within 72 hours of rash onset for zoster; initiated at earliest sign/symptom for chickenpox; prodrome for intermittent therapy). The AI claims include onset-time statements but omit label-based initiation timing details.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Contradicted route/form and indication claims (topical ointment/cold sores/HSV-1) and unsupported timing/mechanism claims could mislead about appropriate formulation/indication and expected onset, which is potentially clinically material.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Several claims are contradicted or unsupported by the provided FDA label excerpts, especially around topical ointment and cold sores/HSV-1 indications and multiple efficacy timing/mechanism statements.
Suggested Improvement
Limit claims to the provided indications (herpes zoster, genital herpes, chickenpox) and oral/IV formulations described; remove topical ointment availability and cold-sore/HSV-1 claims; avoid specific onset-time (30 minutes–1 hour) and mechanism assertions not present in the supplied label text; use label-supported regimen details and initiation timing (earliest sign/symptom; zoster within 72 hours; prodrome for recurrence).